STUDY OBJECTIVE: Atrial fibrillation affects more than 2 million people in the United States and accounts for nearly 1% of emergency department (ED) visits. Physicians have little information to guide risk stratification of patients with symptomatic atrial fibrillation and admit more than 65%. Our aim is to assess whether data available in the ED management of symptomatic atrial fibrillation can estimate a patient's risk of experiencing a 30-day adverse event. METHODS: We systematically reviewed the electronic medical records of all ED patients presenting with symptomatic atrial fibrillation between August 2005 and July 2008. Predefined adverse outcomes included 30-day ED return visit, unscheduled hospitalization, cardiovascular complication, or death. We performed multivariable logistic regression to identify predictors of 30-day adverse events. The model was validated with 300 bootstrap replications. RESULTS: During the 3-year study period, 914 patients accounted for 1,228 ED visits. Eighty patients were excluded for non-atrial-fibrillation-related complaints and 2 patients had no follow-up recorded. Of 832 eligible patients, 216 (25.9%) experienced at least 1 of the 30-day adverse events. Increasing age (odds ratio [OR] 1.20 per decade; 95% confidence interval [CI] 1.06 to 1.36 per decade), complaint of dyspnea (OR 1.57; 95% CI 1.12 to 2.20), smokers (OR 2.35; 95% CI 1.47 to 3.76), inadequate ventricular rate control (OR 1.58; 95% CI 1.13 to 2.21), and patients receiving β-blockers (OR 1.44; 95% CI 1.02 to 2.04) were independently associated with higher risk for adverse events. C-index was 0.67. CONCLUSION: In ED patients with symptomatic atrial fibrillation, increased age, inadequate ED ventricular rate control, dyspnea, smoking, and β-blocker treatment were associated with an increased risk of a 30-day adverse event.
STUDY OBJECTIVE:Atrial fibrillation affects more than 2 million people in the United States and accounts for nearly 1% of emergency department (ED) visits. Physicians have little information to guide risk stratification of patients with symptomatic atrial fibrillation and admit more than 65%. Our aim is to assess whether data available in the ED management of symptomatic atrial fibrillation can estimate a patient's risk of experiencing a 30-day adverse event. METHODS: We systematically reviewed the electronic medical records of all ED patients presenting with symptomatic atrial fibrillation between August 2005 and July 2008. Predefined adverse outcomes included 30-day ED return visit, unscheduled hospitalization, cardiovascular complication, or death. We performed multivariable logistic regression to identify predictors of 30-day adverse events. The model was validated with 300 bootstrap replications. RESULTS: During the 3-year study period, 914 patients accounted for 1,228 ED visits. Eighty patients were excluded for non-atrial-fibrillation-related complaints and 2 patients had no follow-up recorded. Of 832 eligible patients, 216 (25.9%) experienced at least 1 of the 30-day adverse events. Increasing age (odds ratio [OR] 1.20 per decade; 95% confidence interval [CI] 1.06 to 1.36 per decade), complaint of dyspnea (OR 1.57; 95% CI 1.12 to 2.20), smokers (OR 2.35; 95% CI 1.47 to 3.76), inadequate ventricular rate control (OR 1.58; 95% CI 1.13 to 2.21), and patients receiving β-blockers (OR 1.44; 95% CI 1.02 to 2.04) were independently associated with higher risk for adverse events. C-index was 0.67. CONCLUSION: In ED patients with symptomatic atrial fibrillation, increased age, inadequate ED ventricular rate control, dyspnea, smoking, and β-blocker treatment were associated with an increased risk of a 30-day adverse event.
Authors: D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: Peter Zimetbaum; Matthew R Reynolds; Kalon K L Ho; Thomas Gaziano; Mary Jane McDonald; Seth McClennen; Ronna Berezin; Mark E Josephson; David J Cohen Journal: Am J Cardiol Date: 2003-09-15 Impact factor: 2.778
Authors: Thomas J Wang; Joseph M Massaro; Daniel Levy; Ramachandran S Vasan; Philip A Wolf; Ralph B D'Agostino; Martin G Larson; William B Kannel; Emelia J Benjamin Journal: JAMA Date: 2003-08-27 Impact factor: 56.272
Authors: Tyler W Barrett; Alan B Storrow; Cathy A Jenkins; Robert L Abraham; Dandan Liu; Karen F Miller; Kelly M Moser; Stephan Russ; Dan M Roden; Frank E Harrell; Dawood Darbar Journal: Am J Cardiol Date: 2015-01-06 Impact factor: 2.778
Authors: Benjamin A Goldstein; Ann Marie Navar; Michael J Pencina; John P A Ioannidis Journal: J Am Med Inform Assoc Date: 2016-05-17 Impact factor: 4.497
Authors: Shiva K Ratuapli; Adil E Bharucha; Jessica Noelting; Doris M Harvey; Alan R Zinsmeister Journal: Gastroenterology Date: 2012-11-07 Impact factor: 22.682
Authors: Tyler W Barrett; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; Karen F Miller; Kelly M Moser; Stephan Russ; Dan M Roden; Dawood Darbar Journal: J Cardiol Date: 2011-08-04 Impact factor: 3.159
Authors: Tyler W Barrett; Robert L Abraham; Cathy A Jenkins; Stephan Russ; Alan B Storrow; Dawood Darbar Journal: Am J Cardiol Date: 2012-07-26 Impact factor: 2.778
Authors: Tyler W Barrett; Wesley H Self; Brian S Wasserman; Candace D McNaughton; Dawood Darbar Journal: Am J Emerg Med Date: 2013-03-09 Impact factor: 2.469